|
Getting your Trinity Audio player ready...
|
Pandorum Technologies is a biotechnology company specializing in tissue engineering and regenerative medicine. The company focuses on developing therapeutic products aimed at treating conditions related to corneal dystrophies, lung disorders, and liver diseases. Its core offerings include bio-engineered human tissues, such as cornea and liver, intended for medical research and therapeutic applications.
Company Overview
Founded in 2011 in Bengaluru, India, Pandorum Technologies was established by Dr. Tuhin Bhowmick and Dr. Arun Chandru. The company’s vision is to utilize principles of biology and engineering to design therapeutic products that address unmet clinical needs in regenerative medicine.
| Specifications | Details |
| Company Name | Pandorum Technologies Pvt. Ltd. |
| Founded Year | 2011 |
| Founders | Dr. Tuhin Bhowmick and Dr. Arun Chandru |
| Industry Focus | Biotechnology, Tissue Engineering, Regenerative Medicine |
| Net Worth (2023) | Approx. $48.3 Million |
| Annual Sales Revenue (2023) | Approx. $3.7 Million |
| Core Offerings | Bio-engineered human tissues (Cornea, Liver), Therapeutic products, 3D Tissue Platforms |
| Social Profiles | Facebook | LinkedIn | Instagram| |
| Target Markets | Healthcare, Biomedical Research, Regenerative Medicine, Organ Replacement Therapies |
| Website | www.pandorum.com |
Unique Approach
Pandorum employs proprietary technology platforms to develop functional human tissues. Their approach includes modulating stem cell-derived exosomes and priming them to deliver therapeutic cargos. Additionally, they have capabilities in building 3D functional tissues through a combination of cells, gels, and cell modulators, using self-assembly, 3D printing, and other fabrication methods to construct tissue-like micro-architecture.
Market Impact/Problem Solved
The company addresses the shortage of human donor organs by developing bio-engineered tissues, thereby aiming to make organ replacement more accessible and affordable. Their innovations, such as the bio-engineered cornea, are designed to treat various corneal disorders, potentially reducing dependency on donor tissues.
Collaborations & Achievements
In March 2022, Pandorum partnered with Wipro Limited to integrate artificial intelligence capabilities into regenerative medicine, aiming to accelerate the development of advanced therapeutics. The company has also been recognized with awards such as the Top Innovator Award at the ET Startup Awards in 2018.
Sustainability/Innovation
Pandorum is developing cell-free therapies for tissue repair and regeneration, focusing on sustainable and scalable solutions in regenerative medicine. Their work in exosome and nanotherapy involves using mesenchymal stem cell-derived exosomes with therapeutic potential, representing a novel approach in the field.
Leadership/Founder Insights
Dr. Tuhin Bhowmick, co-founder and CEO, holds a Ph.D. from the Indian Institute of Science (IISc), Bangalore, and has post-doctoral experience from the European Molecular Biology Laboratory. His expertise includes biophysics, crystallography, biomaterials, and computational biology. Co-founder and CTO, Dr. Arun Chandru, earned his M.Sc. (Engg.) from IISc, Bangalore, and was featured in Forbes Asia’s ’30 under 30′ list in 2016 for his contributions to healthcare and science.
Conclusion
Pandorum Technologies contributes to the field of regenerative medicine by developing bio-engineered human tissues and innovative therapeutic solutions. Through their unique methodologies and strategic collaborations, they aim to address critical challenges in organ transplantation and tissue regeneration, potentially impacting patient care and treatment outcomes in the future.
Don’t miss: Groww Company Profile Revolutionizing Online Investing in India
Leave feedback about this